Core Insights - Eli Lilly and Company plans to invest over $1.2 billion to expand and modernize its manufacturing site in Carolina, Puerto Rico, creating 100 manufacturing jobs and up to 1,000 construction jobs [1][4] Group 1: Investment and Expansion - The investment will integrate advanced technologies and expand production capacity for oral solid medicines in areas such as cardiometabolic health, neuroscience, oncology, and immunology [1][2] - The facility will manufacture orforglipron, Lilly's first oral GLP-1 receptor agonist, with regulatory submissions expected by the end of the year [2] - This expansion is part of a broader $50 billion capital investment commitment to enhance U.S. manufacturing capacity [2] Group 2: Technological Advancements - The upgraded facility will utilize advanced manufacturing technologies, including dock-to-dock automation, paperless manufacturing, and process analytical technology [3] - These technologies aim to improve the absorption of oral medicines through methods like spray-dried dispersion [3] Group 3: Economic Impact - The project is expected to generate significant local employment, with 1,000 construction jobs and 100 high-tech manufacturing positions [4] - The investment reflects a commitment to Puerto Rico as a strategic hub for advanced manufacturing and innovation, enhancing the local economy [5] Group 4: Timeline - Construction of the expanded facility is estimated to begin in 2026, with production expected to start by the end of 2028 [4]